Samin Fallah Pakdaman
Research Subjects
Samin Fallah Pakdaman has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Ali Nabipour
School of Pharmacy, Kermanshah University of Medical Sciences
2 shared publications - Alireza Falahati Marvast
School of Pharmacy, Shahid Sadoughi University of Medical Sciences
2 shared publications - Arad Shadi
School of Pharmacy, Tabriz University of Medical Sciences
2 shared publications - Helia Azmakan
Department of Clinical Pharmacy, Faculty of Pharmacy Tehran Azad University of Medical Sciences Tehran Iran
2 shared publications - Mobina Shieh
Department of Clinical Pharmacy, Faculty of Pharmacy Tehran Medical Sciences Islamic Azad University Tehran Iran
2 shared publications - Negin Asemi Sichani
Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences
2 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by Elsevier in Intelligence-Based Medicine
- Vol. 15
ChatGPT as a digital pharmacist: A systematic review of medication counselling accuracy
- 19 June 2026
- Published by Elsevier in Intelligence-Based Medicine
- Vol. 15
Open AccessChatGPT as a digital pharmacist: A systematic review of medication counselling accuracy
- Open Access
ChatGPT as a Digital Pharmacist: A Systematic Review and Meta-Analysis of Drug-Counselling Accuracy
Background The emergence of Large Language Models (LLMs) like ChatGPT presents significant opportunities for healthcare, yet raises concerns about accuracy, especially in high-risk areas such as medication counseling. A comprehensive evaluation of ChatGPT’s reliability in providing drug information is crucial for its safe integration into clinical practice. This systematic review and meta-analysis aimed to assess the accuracy of drug-counseling information provided by ChatGPT 4. Methods Following PRISMA, we systematically searched PubMed, Embase, Scopus, and Web of Science on May 9, 2025, for original research evaluating the accuracy of ChatGPT (version 4 or newer) in drug-counseling queries. Included studies compared the AI’s output against standard comparators like pharmacists or drug databases. A random-effects meta-analysis was performed to calculate the pooled proportion of accurate responses, and study quality was assessed using a customized Newcastle-Ottawa Scale (NOS). Results The search identified 17 eligible studies. Of these, 15 were included in the meta-analysis, which showed a pooled accuracy rate of 86% (95% CI: 0.75–0.95). However, significant heterogeneity was observed across studies (I2=98.5%, pConclusion ChatGPT demonstrates substantial promise in drug counseling, with an 86% accuracy rate that surpasses its performance in other medical domains. However, the high heterogeneity and a non-trivial 14% error rate, coupled with methodological weaknesses in the primary literature, indicate that ChatGPT is not yet ready for autonomous clinical use. Its current role should be as a supplementary tool under the strict supervision of qualified healthcare professionals to ensure patient safety.
Open AccessChatGPT as a Digital Pharmacist: A Systematic Review and Meta-Analysis of Drug-Counselling Accuracy
Background The emergence of Large Language Models (LLMs) like ChatGPT presents significant opportunities for healthcare, yet raises concerns about accuracy, especially in high-risk areas such as medication counseling. A comprehensive evaluation of ChatGPT’s reliability in providing drug information is crucial for its safe integration into clinical practice. This systematic review and meta-analysis aimed to assess the accuracy of drug-counseling information provided by ChatGPT 4. Methods Following PRISMA, we systematically searched PubMed, Embase, Scopus, and Web of Science on May 9, 2025, for original research evaluating the accuracy of ChatGPT (version 4 or newer) in drug-counseling queries. Included studies compared the AI’s output against standard comparators like pharmacists or drug databases. A random-effects meta-analysis was performed to calculate the pooled proportion of accurate responses, and study quality was assessed using a customized Newcastle-Ottawa Scale (NOS). Results The search identified 17 eligible studies. Of these, 15 were included in the meta-analysis, which showed a pooled accuracy rate of 86% (95% CI: 0.75–0.95). However, significant heterogeneity was observed across studies (I2=98.5%, pConclusion ChatGPT demonstrates substantial promise in drug counseling, with an 86% accuracy rate that surpasses its performance in other medical domains. However, the high heterogeneity and a non-trivial 14% error rate, coupled with methodological weaknesses in the primary literature, indicate that ChatGPT is not yet ready for autonomous clinical use. Its current role should be as a supplementary tool under the strict supervision of qualified healthcare professionals to ensure patient safety.
- Open Access
- 3 June 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (9) , 2973-2981
Fabrication and efficacy assessment of combination of brimonidine and ivermectin for treatment of papulopustular rosacea
Background & Aim: Rosacea is a chronic inflammatory, multifactorial disease for which combination therapy could be an effective treatment. In this study, we evaluate the effect of the combination therapy of brimonidine 0.33% and ivermectin 1% as a single cream for the treatment of papulopustular rosacea. Method: A stable and appropriate formulation was prepared by adding the aqueous phase to the lipid phase while being stirred. The stability and physicochemical properties of the formulation were evaluated under accelerated conditions. Twelve patients (36–60 years) with mild to moderate papulopustular rosacea and a Demodex count of five or more were treated with the combination of brimonidine 0.33% and ivermectin 1% cream. Clinician's Erythema Assessment (CEA), Patients Self‐Assessment (PSA), skin erythema (ΔE) and lightness (ΔL), and skin biophysical parameters including transepidermal water loss (TEWL), skin hydration, pH, and sebum content, as well as erythema and melanin index and ultrasound parameters, were measured before treatment and 4 and 8 weeks after. Adverse drug reactions were also recorded. Results: CEA and PSA decreased significantly from 3 to 2 after 8 weeks, respectively ( p ‐value = 0.014 for CEA and 0.010 for PSA). ΔE and ΔL, as well as skin erythema index and TEWL improved after 8 weeks of treatment ( p < 0.05). Two patients withdrew from the study in the first week because of local adverse effects; one developed flushing following treatment and left the investigation after 4 weeks and another patient withdrew from the study after 4 weeks due to deciding to become pregnant. Conclusion: Eight‐week treatment with the combination of brimonidine 0.33% and ivermectin 1% was shown to be effective for improvement of erythema and inflammatory lesions in mild to moderate papulopustular rosacea.
- 3 June 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (9) , 2973-2981
Open AccessFabrication and efficacy assessment of combination of brimonidine and ivermectin for treatment of papulopustular rosacea
Background & Aim: Rosacea is a chronic inflammatory, multifactorial disease for which combination therapy could be an effective treatment. In this study, we evaluate the effect of the combination therapy of brimonidine 0.33% and ivermectin 1% as a single cream for the treatment of papulopustular rosacea. Method: A stable and appropriate formulation was prepared by adding the aqueous phase to the lipid phase while being stirred. The stability and physicochemical properties of the formulation were evaluated under accelerated conditions. Twelve patients (36–60 years) with mild to moderate papulopustular rosacea and a Demodex count of five or more were treated with the combination of brimonidine 0.33% and ivermectin 1% cream. Clinician's Erythema Assessment (CEA), Patients Self‐Assessment (PSA), skin erythema (ΔE) and lightness (ΔL), and skin biophysical parameters including transepidermal water loss (TEWL), skin hydration, pH, and sebum content, as well as erythema and melanin index and ultrasound parameters, were measured before treatment and 4 and 8 weeks after. Adverse drug reactions were also recorded. Results: CEA and PSA decreased significantly from 3 to 2 after 8 weeks, respectively ( p ‐value = 0.014 for CEA and 0.010 for PSA). ΔE and ΔL, as well as skin erythema index and TEWL improved after 8 weeks of treatment ( p < 0.05). Two patients withdrew from the study in the first week because of local adverse effects; one developed flushing following treatment and left the investigation after 4 weeks and another patient withdrew from the study after 4 weeks due to deciding to become pregnant. Conclusion: Eight‐week treatment with the combination of brimonidine 0.33% and ivermectin 1% was shown to be effective for improvement of erythema and inflammatory lesions in mild to moderate papulopustular rosacea.